MDXG (MiMedx Group) Marketable Securities: $0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDXG MiMedx Group Inc MDXG
53 GF Score
Price $4.17
GF Value $6.81
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is MiMedx Group Marketable Securities?

MiMedx Group MDXG +2.08% 53 Marketable Securities is $0.0 Mil as of Mar. 2026. GuruFocus rates MDXG with a GF Score™ of 53/100 and a GF Value™ of $6.81 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. MiMedx Group's Marketable Securities for the quarter that ended in Mar. 2026 was $0.0 Mil.

MiMedx Group  (NAS:MDXG) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

MiMedx Group Marketable Securities Related Terms

MiMedx Group Marketable Securities Historical Data

* Premium members only.

The historical data trend for MiMedx Group's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MiMedx Group Marketable Securities Chart

MiMedx Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MiMedx Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MDXG
53GF Score
MiMedx Group Inc MDXG
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MiMedx Group Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $0.0 Mil mean?
MiMedx Group (MDXG) has a Marketable Securities of $0.0 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on MiMedx Group and its competitors.
Is MiMedx Group's Marketable Securities too high?
MiMedx Group's current Marketable Securities is $0.0 Mil. Overall, MiMedx Group has a GF Score™ of 53/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MiMedx Group's Marketable Securities compare to MNPR and FTH?
MiMedx Group's Marketable Securities of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on MiMedx Group and its competitors. MiMedx Group's current Marketable Securities is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiMedx Group stock overvalued right now?
Based on GuruFocus' analysis, MiMedx Group (MDXG) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.81, compared to a current price of $4.17 — trading 38.8% below its estimated fair value. The current Marketable Securities is $0.0 Mil. MiMedx Group's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For MiMedx Group (MDXG), the current Marketable Securities is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MiMedx Group (MDXG) Overvalued in 2026?

Based on GuruFocus' analysis, MiMedx Group stock appears to be undervalued. The current stock price of $4.17 is trading 38.8% below its estimated GF Value™ of $6.81. GuruFocus considers MiMedx Group to be Significantly Undervalued.

Key valuation signals for MDXG:

  • Marketable Securities: $0.0 Mil
  • GF Value™: $6.81 vs. price of $4.17 (38.8% below fair value)
  • GF Score™: 53/100 with 2 warning signs

No single metric tells the full story. See the MDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MiMedx Group Business Description

Address 1775 West Oak Commons Court, NE, Marietta, GA, USA, 30062
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
53GF Score

Get the complete analysis for MDXG

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.17
Price
$6.81
GF Value